NCT00501735已完成2 期
Single Agent Phase II Study of Forodesine (BCX1777) in the Treatment of Cutaneous T-Cell Lymphoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 144
- 试验地点
- 82
- 主要终点
- The primary objective of this study is to determine the objective response rate to treatment with oral forodesine in subjects with cutaneous manifestations of CTCL subjects, stages IIB, III, and IVA.
研究概览
简要总结
This is a Phase II, non-randomized, open-label, single-arm trial that will be conducted at up to 50 sites in North America, Europe and Australia. This study is designed to assess objective response (OR) [complete response (CR) or partial response (PR)] in subjects with cutaneous manifestations of CTCL with a requirement for maintenance of such objective response for at least 28 days in subjects with stage IIB, III, and IVA CTCL. Additionally, this study will evaluate the safety and tolerability of CTCL subjects Stages IB, IIA, IIB, III, or IVA treated with oral forodesine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or non-pregnant females aged ≥18 years;
- •Histologically confirmed diagnosis of CTCL, including mycosis fungoides and/or Sezary syndrome, documentation of diagnosis by histologic examination should be available;
- •Subjects with CTCL stages IB, IIA, IIB, III, or IVA at the screening visit (i.e. stage refers to stage at study entry) and who have persistent, progressive, or recurrent disease during or following treatment with at least three forms of systemic therapy, one of which must have been oral bexarotene, unless treatment with oral bexarotene was not tolerated or was medically contraindicated;
- •Anticipated life expectancy greater than 6 months;
- •Performance status of 0, 1, or 2 by Eastern Cooperative Oncology Group (ECOG) criteria;
- •Females of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of study treatment;
- •Females of childbearing potential and sexually active males, if indicated, must be willing and able to use method(s) of contraception that are adequate to prevent or minimize the risk of pregnancy for the duration of the study;
- •Written informed consent to participate in the study.
排除标准
- •Proven or suspected extracutaneous visceral CTCL involvement (M1) (CTCL stage IVB) (note: presence of lymphadenopathy is permitted);
- •Previous treatment with Forodesine;
- •ECOG performance status >2;
- •Concomitant use of any anti-cancer therapy or immune modifier;
- •Concomitant use of any investigational agent or device;
- •Concurrent treatment with any other anti-CTCL therapy, or radiation therapy [topical corticosteroids (classes 1 and 2 prohibited) or low dose oral corticosteroids (≤10 mg/day prednisone or equivalent) will not be excluded, but if used, must be a stable dose and schedule during the four weeks immediately prior to study entry];
- •Use of previous therapies for CTCL within the timeframes specified below:
- •Phototherapy in the previous 30 days;
- •Electron beam therapy, photopheresis, systemic anticancer therapy, interferon therapy, or other investigational therapy in the previous 30 days;
- •Oral retinoid (including bexarotene) in the previous 30 days
- •Alemtuzumab (Campath) or other monoclonal antibody within the previous 30 days
- •Vorinostat or other HDAC inhibitor within previous 30 days
- •Any investigational therapy within the previous 30 days;
- •ALT or AST >3 times ULN or alkaline phosphatase >2 times ULN;
- •Calculated creatinine clearance ≤50 mL/min or serum creatinine ≥1.8 mg/dL;
- •Serum potassium <3.3 mg/dL or >5.5 mg/dL;
- •Evidence of clinically significant (uncontrolled) hypo- or hyperthyroidism;
- •Recent (in past 6 months) medically significant cardiac event (i.e., myocardial infarction, cardiac surgery);
- •Presence of congestive heart failure (NYHA class IV) or angina (NYHA class IV) or presence of a medically significant dysrhythmia;
- •Presence of any of the following ECG findings:
- •Congenital long QT syndrome;
- •QTc interval >480 msec (Bazett's correction);
- •Presence of uncontrolled hypertension manifested by systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥90 mmHg;
- •Hemoglobin <9.0 gm/dL (intermittent red blood cell transfusions permitted);
- •Absolute neutrophil count <1500 cells/mm3;
- •Platelet count <75,000/mm3;
- •Requirement for neutrophil or platelet growth factor therapy or administration of such therapy in the previous 30 days;
- •CD4 count <200/mm3;
- •Documented current active infection with HIV, Hepatitis B, Hepatitis C, and/or CMV;
- •Presence of uncontrolled bacterial or viral infection (subject may be receiving chronic antimicrobial therapy); or,
- •History of culture-documented bacteremia in the previous 2 weeks;
- •Recent (i.e., in past 2 weeks) change in doses or regimens of medications used for any chronic non-oncologic condition for reasons of worsening of the chronic illness (change in doses of chronic medications associated with improvement in a chronic illness are not exclusionary);
- •Presence of any acute or chronic non-oncologic disease which, in the opinion of the investigator, is medically uncontrolled;
- •Coexistent second malignancy or history of prior malignancy within previous 5 years [excluding basal cell or squamous cell carcinoma of skin and cervical neoplasia (carcinoma-in-situ) that has been treated curatively]. Surgically resected nonmelanomatous skin cancer (non-CTCL) with no evidence of recurrence in previous 6 months is permitted; and,
- •Any significant medical or psychiatric condition that, in the opinion of the investigator, might prevent the subject from complying with all required study procedures.
结局指标
主要结局
The primary objective of this study is to determine the objective response rate to treatment with oral forodesine in subjects with cutaneous manifestations of CTCL subjects, stages IIB, III, and IVA.
时间窗: Duration of Study
次要结局
- Safety and tolerability(Duration of Study)
- Time to and duration of objective response in cutaneous manifestations(Duration of Study)
- Time to loss of objective response(Duration of Study)
- Objective response rate, time to and duration of extracutaneous manifestations(Duration of Study)
- Health related quality of life(Duration of Study)
研究者
研究点 (82)
Loading locations...
相似试验
Unknown
2 期
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's DiseaseAlzheimer DiseaseNCT01680588Navidea Biopharmaceuticals70
Unknown
2 期
PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell LymphomaNK/T-cell LymphomaNCT03701022Peking University61
招募中
2 期
A clinical trial to study the effects and the antiviral activity of TMC278 in HIV-1 infected adolescent patients aged 12 to 18 yearsCTRI/2011/06/001796Johnson and johnson Ltd35
进行中（未招募）
1 期
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and children aged greater than or equal to 6 yearsEUCTR2008-001696-30-Outside-EU/EEAJanssen Sciences Ireland UC
进行中（未招募）
不适用
A safety study to evaluate the antiviral activity of darunavir in combination with ritonavir in HIV 1 infected adolescents between 12 and 18 years of age who have not received previous treatment with antiretroviral drugsHIV-1MedDRA version: 14.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2008-004631-37-Outside-EU/EEATibotec Pharmaceuticals12